A Partner Grant from the Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS) will support a research project focused on possible connections between air pollution and outcomes of people with sarcoidosis. The grant, totaling $100,000 over two years, was awarded to Mark Mallozzi, MD,…

The first participants in a Phase 2 clinical trial testing brepocitinib, Roivant’s experimental oral treatment, in adults with cutaneous sarcoidosis have been dosed, and top-line results are expected in the second half of 2026. The company had this year announced plans to launch this proof-of-concept trial, called BEACON…

Methotrexate appears to take longer to start acting, but is no less effective than the corticosteroid prednisone as a first-line treatment for pulmonary sarcoidosis, according to the early findings of an ongoing Phase 4 clinical trial. The researchers noted that, while methotrexate treatment is associated with a similar number…

Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that can have serious side effects, according to real-world analyses. “New real-world evidence underscores the growing burden of patients…

The prevalence of sarcoidosis, or the proportion of people with the condition in a population, has roughly doubled over the past 30 years in a region in Norway, a large population-based study shows, and the incidence of sarcoidosis, that is, the number of new cases within a given time,…

April has officially been recognized as Sarcoidosis Awareness Month in the U.S., marking a significant milestone for the community and its advocates, according to the Foundation for Sarcoidosis Research (FSR) — which also celebrates its 25th anniversary this year. The recognition by the U.S. Congress was spearheaded by Danny…

More than two dozen mutations that seem to increase the risk of developing sarcoidosis were identified in a new study. Notably, 17 of the 28 mutations hadn’t been linked to the inflammatory disease. Higher genetically predicted body mass index (BMI) and higher levels of several proteins involved in inflammation…

The findings of a new preclinical study in pulmonary sarcoidosis are lending support to the therapeutic potential of efzofitimod, a treatment candidate from Atyr Pharma now being tested in a Phase 3 clinical trial. The researchers found that a protein called HARS-WHEP — whose activity is mimicked by…

Dearly beloved, Earlier this month, my husband and I attended our niece’s wedding. Later this month, we’ll renew our vows to celebrate our 25th wedding anniversary. It’s no surprise that in between the two events, I’ve been reflecting on love, marriage, and what we mean when we say “I do.”…

Nearly 1 in 10 people with pulmonary sarcoidosis also have heart involvement, or cardiac sarcoidosis, at the time of their initial diagnosis with the rare inflammatory disease occurring in the lungs, according to a study in Japan. Further, another 3.8% of patients subsequently develop cardiac sarcoidosis, the data…